Literature DB >> 11973006

Case reports - reversal of sensory deficit associated with pain relief after treatment with gabapentin.

M S Chong1, T E Smith, M Hanna.   

Abstract

Many patients with neuropathic pain have coexistent sensory deficits. Neuropathic pain may be alleviated by a variety of drugs but sensory deficits are assumed to be permanent. In an audit of the effects of gabapentin therapy on patients with neuropathic pain, monthly detailed sensory examinations were performed during the first three months of treatment. Of five patients with sensory deficits who tolerated gabapentin therapy, three showed marked improvement of their sensory deficits associated with pain alleviation. The cases are presented and possible explanations for the observed sensory improvements are discussed. These findings raised exciting neurophysiological questions in addition to being of potential importance to the clinical problem of neurotrophic tissue injury.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11973006     DOI: 10.1016/S0304-3959(01)00468-7

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  3 in total

1.  5% lidocaine medicated plaster double effect in a case of orofacial localized neuropathic pain.

Authors:  Roberto Casale; Yuriy Romanenko; Massimo Allegri
Journal:  J Pain Res       Date:  2014-11-24       Impact factor: 3.133

2.  A Meta-Analysis of Therapeutic Efficacy and Safety of Gabapentin in the Treatment of Postherpetic Neuralgia from Randomized Controlled Trials.

Authors:  Meng Zhang; Cun-Xiang Gao; Ke-Tao Ma; Li Li; Zhi-Gang Dai; Sheng Wang; Jun-Qiang Si
Journal:  Biomed Res Int       Date:  2018-07-04       Impact factor: 3.411

3.  Randomised controlled trial of gabapentin in Complex Regional Pain Syndrome type 1 [ISRCTN84121379].

Authors:  Anton C van de Vusse; Suzanne G M Stomp-van den Berg; Alfons H F Kessels; Wim E J Weber
Journal:  BMC Neurol       Date:  2004-09-29       Impact factor: 2.474

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.